Monopar Therapeutics (MNPR) EPS (Basic) (2017 - 2025)
Quarterly results put EPS (Basic) at -$0.48 for Q3 2025, down 29.73% from a year ago — trailing twelve months through Dec 2025 was -$1.21 (up 11.68% YoY), and the annual figure for FY2024 was -$4.11, down 35.64%.
Monopar Therapeutics has reported EPS (Basic) over the past 9 years, most recently at -$0.48 for Q3 2025.
- EPS (Basic) reached -$0.48 in Q3 2025 per MNPR's latest filing, down from -$0.35 in the prior quarter.
- Across five years, EPS (Basic) topped out at -$0.16 in Q1 2021 and bottomed at -$1.1 in Q4 2022.
- Median EPS (Basic) over the past 5 years was -$0.22 (2022), compared with a mean of -$0.36.
- The largest annual shift saw EPS (Basic) plummeted 426.08% in 2022 before it soared 46.38% in 2024.
- Over 5 years, EPS (Basic) stood at -$0.21 in 2021, then tumbled by 426.08% to -$1.1 in 2022, then surged by 37.54% to -$0.69 in 2023, then skyrocketed by 46.38% to -$0.37 in 2024, then fell by 29.73% to -$0.48 in 2025.
- Business Quant data shows EPS (Basic) for MNPR at -$0.48 in Q3 2025, -$0.35 in Q2 2025, and -$0.38 in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 3.06 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 0.00 |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 4.06 |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 6.99 |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | 0.00 |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 1.55 |
| 10 | Monopar Therapeutics | 466.82 Mn | 466.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -0.48 |
| Jun 30, 2025 | -0.35 |
| Mar 31, 2025 | -0.38 |
| Sep 30, 2024 | -0.37 |
| Jun 30, 2024 | -0.49 |
| Mar 31, 2024 | -0.51 |
| Sep 30, 2023 | -0.69 |
| Jun 30, 2023 | -0.16 |
| Mar 31, 2023 | -0.19 |
| Dec 31, 2022 | -1.10 |
| Sep 30, 2022 | -0.19 |
| Jun 30, 2022 | -0.22 |
| Mar 31, 2022 | -0.19 |
| Dec 31, 2021 | -0.21 |
| Sep 30, 2021 | -0.20 |
| Jun 30, 2021 | -0.17 |
| Mar 31, 2021 | -0.16 |
| Dec 31, 2020 | -0.19 |
| Sep 30, 2020 | -0.15 |
| Jun 30, 2020 | -0.14 |
| Mar 31, 2020 | -0.10 |
| Dec 31, 2019 | -0.13 |
| Sep 30, 2019 | -0.08 |
| Jun 30, 2019 | -0.10 |
| Mar 31, 2019 | -0.15 |
| Dec 31, 2018 | -0.10 |
| Sep 30, 2018 | -0.07 |
| Jun 30, 2018 | -0.07 |
| Mar 31, 2018 | -0.09 |
| Dec 31, 2017 | -0.05 |
| Sep 30, 2017 | -1.68 |
| Jun 30, 2017 | -0.07 |
| Mar 31, 2017 | -0.04 |